Year: 2026
Type: article
Abstract: Despite improved outcomes with neoadjuvant chemoimmunotherapy in resectable non–small cell lung cancer (NSCLC), variability in pathological nodal response persists. This study aimed to identify predictors of pathological nodal non-response and to evaluate its impact on recurrence-free survival (RFS).
Source: ESMO Open
Authors: G. Yavuz, R. Tajè, R. Rayes, J. Cools-Lartigue, S. Najmeh, M. Rousseau, L. Ferri, L. Ofiara, B. Shieh, S. Owen, A. Wong, P-O. Fiset, J. Spicer
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, United Therapeutics Corporation, Varian Medical Systems, Boston Scientific Corporation, Regeneron Pharmaceuticals, Intuitive Surgical, Cook Medical, Jazz Pharmaceuticals, Novocure, Auris Health, Mirati Therapeutics, Revolution Medicines, Genentech, EMD Serono, Sanofi Genzyme
OpenAlex ID: W7138337679
FWCI:
Cites:
Cited by:
Related to: